The telomerase inhibitor imetelstat differentially targets JAK2V617F versus CALR mutant myeloproliferative neoplasm cells and inhibits JAK-STAT signaling.
Frontiers in oncology
View this publicationFrontiers in oncology
View this publicationEuropean journal of haematology
View this publicationInfection
View this publicationOrphanet journal of rare diseases
View this publicationPublication categories: Top publication
Nature communications
View this publicationAllergy
View this publicationBMC cardiovascular disorders
View this publicationDevelopmental cell
View this publicationScientific reports
View this publicationCell research
View this publication